Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Aug 10, 2022 (4 years ago)

PF-0.125% Bupivacaine HCl Injection

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations: Potential for cross-contamination due to product carryover during manufacturing.

Cause type: Cross-contamination

Traces of another drug - most often penicillin - got into the product from shared equipment or facilities. Even trace penicillin can trigger a severe allergic reaction in someone who was never meant to receive it. All cross-contamination recalls.

What was recalled

PF-0.125% Bupivacaine HCl Injection, USP, 625 mg/500 mL (1.25 mg/mL), 500 mL bag, packaged in 10 x 1 IV Bag per case, Rx Only, Nephron 503B Outsourcing Facility, 4500 12th Street Extension, West Columbia, SC 29172; NDC 69374-970-05

Affected NDC 69374-0970-05

Compare with the code on your package — it is the most precise check available.

Drug: Bupivacaine

Recalling firm
Nephron Sterile Compounding Center LLC
NDC code
69374-970-05
Origin
SC, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1346-2022 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Bupivacaine recalls

See all

Other recalls by Nephron Sterile Compounding Center LLC

All 2022 recalls